Margaret McGlynn Net Worth

The estimated Net Worth of Margaret G Mcglynn is at least $5.52 Milione dollars as of 12 June 2024. Ms. Mcglynn owns over 6,670 units of Vertex Pharmaceuticals stock worth over $4,970,528 and over the last 20 years she sold VRTX stock worth over $0. In addition, she makes $545,006 as Independent Director at Vertex Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. McGlynn VRTX stock SEC Form 4 insiders trading

Margaret has made over 23 trades of the Vertex Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently she exercised 6,670 units of VRTX stock worth $3,166,516 on 12 June 2024.

The largest trade she's ever made was exercising 20,000 units of Vertex Pharmaceuticals stock on 9 January 2020 worth over $66,400. On average, Margaret trades about 1,725 units every 30 days since 2005. As of 12 June 2024 she still owns at least 10,470 units of Vertex Pharmaceuticals stock.

You can see the complete history of Ms. Mcglynn stock trades at the bottom of the page.

Margaret McGlynn biography

Margaret G. McGlynn is Independent Director of Vertex Pharmaceuticals Incorporated. Ms. McGlynn retired from Merck & Co. in 2009, where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products. During her 26 year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn serves as a member of the Board of Directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, and Amicus Therapeutics, Inc., a biopharmaceutical company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. Ms. McGlynn holds a B.S. in Pharmacy and an M.B.A. in Marketing from the State University of New York at Buffalo.

What is the salary of Margaret McGlynn?

As the Independent Director of Vertex Pharmaceuticals, the total compensation of Margaret McGlynn at Vertex Pharmaceuticals is $545,006. There are 14 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.

How old is Margaret McGlynn?

Margaret McGlynn is 60, she's been the Independent Director of Vertex Pharmaceuticals since 2011. There are 5 older and 19 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.

What's Margaret McGlynn's mailing address?

Margaret's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, , 20878.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden e Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.

What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Complete history of Ms. Mcglynn stock trades at Amicus Therapeutics Inc, Novavax, Vertex Pharmaceuticals e Air Products & Chemicals

Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jeffrey Leiden,
  Executive Chairman of the Board
• Stuart Arbuckle,
  Executive Vice President, Chief Commercial Officer
• Reshma Kewalramani,
  President, Chief Executive Officer, Director
• Amit Sachdev,
  Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
• David Altshuler,
  Executive Vice President - Global Research, Chief Scientific Officer
• Michael Parini,
  Executive Vice President, Chief Legal and Administrative Officer
• Dr. Reshma Kewalramani FASN, M.D.,
  CEO, Pres & Director
• Charles Wagner,
  Chief Financial Officer, Executive Vice President
• Paul Silva,
  Senior Vice President, Controller
• Dr. Jeffrey Marc Leiden M.D., Ph.D.,
  Exec. Chairman
• Stuart A. Arbuckle B.Sc.,
  Exec. VP & COO
• Dr. David M. Altshuler,
  Exec. VP of Global Research & Chief Scientific Officer
• Charles F. Wagner Jr.,
  Exec. VP & CFO
• Bruce Sachs,
  Co-Lead Independent Director
• Margaret McGlynn,
  Independent Director
• Terrence Kearney,
  Independent Director
• Sangeeta Bhatia,
  Independent Director
• Yuchun Lee,
  Independent Director
• William Young,
  Independent Director
• Alan Garber,
  Independent Director
• lloyd Carney,
  Independent Director
• Michael Partridge,
  Vice President - Investor Relations
• Diana McKenzie,
  Independent Director
• Nia Tatsis,
  Senior Vice President, Chief Regulatory Officer
• John Gray,
  Senior Vice President, Genetic Therapies
• Gerald Bruce,
  Executive Vice President, Commercial Operations
• Carmen Bozic,
  Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
• Joy Liu,
  Sr. VP & Gen. Counsel
• Damian W. Wilmot Esq.,
  Sr. VP, Chief Risk and Compliance Officer
• Mike Tirozzi,
  SVP and Chief Information & Data Officer
• Kristen Ambrose,
  Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
• Joshua S Boger,
  Chairman & CEO
• Elaine Ullian,
  Director
• Ian F Smith,
  SVP & CFO
• Jeffrey Chodakewitz,
  SVP GMDA, CMO
• Thomas Graney,
  Chief Financial Officer
• Michel Lagarde,
  Director
• Wayne Joseph Riley,
  Director
• Peter Mueller,
  CSO & SVP Drug Discovery
• Thomas Connolly,
  SVP, Human Resources
• Kenneth L Horton,
  EVP & Chief Legal Officer
• Megan E Pace,
  SVP, Corp. Communications
• Christiana Stamoulis,
  SVP, Corp Strategy & Bus Devlp
• Matthew Emmens,
  Director
• Lisa Kelly,
  SVP, Human Resources
• Dennis L Winger,
  Director
• Eugene Cordes,
  Director
• Nancy Wysenski,
  EVP & Chief Commercial Officer
• David T Howton,
  SVP
• Kenneth S Boger,
  SVP & General Counsel
• Kurt Graves,
  EVP, Chief Commercial Officer
• John J Alam,
  SVP, Drug Eval. & Appr.
• Stuart J Collinson,
  Director
• Charles A Sanders,
  Director
• Roger W Brimblecombe,
  Director
• Freda C Lewis Hall,
  EVP, Medicines Development
• Eve Elizabeth Slater,
  Director
• Richard C Garrison,
  SVP, Organizational Developmen
• Johanna Messina Power,
  Controller
• Victor A Hartmann,
  EVP, Strategic & Corp. Devlp.
• Eric Brandt,
  Director
• Lynne H Brum,
  VP, Corp. Comm.&Financial Plan
• Paul A Negulescu,
  VP, Research
• John F Niblack,
  Director
• Iain P M Buchanan,
  VP, European Operations
• Vicki L Sato,
  President
• N Anthony Coles,
  SVP, Comm. Ops.
• Bastiano Sanna,
  EVP, Cell & Genetic Therapies
• Joy Liu,
  SVP, General Counsel
• Kristen Ambrose,
  SVP & Chief Accounting Officer
• Suketu Upadhyay,
  Director
• Jonathan Biller,
  EVP and Chief Legal Officer
• Nancy Thornberry,
  Director
• Edward Morrow Iii Atkinson,
  EVP, Chief Technical Ops. Off.
• Jennifer Schneider,
  Director